New Zealand markets closed
  • NZX 50

    12,541.20
    -40.40 (-0.32%)
     
  • NZD/USD

    0.7093
    +0.0035 (+0.50%)
     
  • NZD/EUR

    0.5907
    +0.0027 (+0.46%)
     
  • ALL ORDS

    7,602.40
    -31.00 (-0.41%)
     
  • ASX 200

    7,360.50
    -25.70 (-0.35%)
     
  • OIL

    71.95
    -0.20 (-0.28%)
     
  • GOLD

    1,821.10
    -40.30 (-2.17%)
     
  • NASDAQ

    13,983.01
    -47.39 (-0.34%)
     
  • FTSE

    7,184.95
    +12.47 (+0.17%)
     
  • Dow Jones

    34,033.67
    -265.63 (-0.77%)
     
  • DAX

    15,710.57
    -18.93 (-0.12%)
     
  • Hang Seng

    28,468.87
    +32.03 (+0.11%)
     
  • NIKKEI 225

    28,995.07
    -295.94 (-1.01%)
     
  • NZD/JPY

    78.4470
    +0.4290 (+0.55%)
     

Akoya to Report First Quarter 2021 Financial Results on May 18, 2021

·1-min read

MARLBOROUGH, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2021 after the market close on Tuesday, May 18, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (833) 562-0146 for domestic callers or (661) 567-1226 for international callers, followed by Conference ID: 7824008. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.

About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.

Investor Contact:
David Deuchler
Gilmartin Group LLC
investors@akoyabio.com

Media Contact:
Michelle Linn
Bioscribe, Inc.
774-696-3803
michelle@bioscribe.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting